TWI721987B - 做為nr2b nmda受體拮抗劑之3,3-二氟哌啶胺基甲酸酯雜環化合物 - Google Patents

做為nr2b nmda受體拮抗劑之3,3-二氟哌啶胺基甲酸酯雜環化合物 Download PDF

Info

Publication number
TWI721987B
TWI721987B TW105117083A TW105117083A TWI721987B TW I721987 B TWI721987 B TW I721987B TW 105117083 A TW105117083 A TW 105117083A TW 105117083 A TW105117083 A TW 105117083A TW I721987 B TWI721987 B TW I721987B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
formula
test
nr2b
Prior art date
Application number
TW105117083A
Other languages
English (en)
Chinese (zh)
Other versions
TW201710248A (zh
Inventor
吉登 夏皮洛
Original Assignee
開曼群島商盧郡控股（開曼）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 開曼群島商盧郡控股（開曼）有限公司 filed Critical 開曼群島商盧郡控股（開曼）有限公司
Publication of TW201710248A publication Critical patent/TW201710248A/zh
Application granted granted Critical
Publication of TWI721987B publication Critical patent/TWI721987B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW105117083A 2015-06-01 2016-05-31 做為nr2b nmda受體拮抗劑之3,3-二氟哌啶胺基甲酸酯雜環化合物 TWI721987B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562169107P 2015-06-01 2015-06-01
US62/169,107 2015-06-01

Publications (2)

Publication Number Publication Date
TW201710248A TW201710248A (zh) 2017-03-16
TWI721987B true TWI721987B (zh) 2021-03-21

Family

ID=57441824

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105117083A TWI721987B (zh) 2015-06-01 2016-05-31 做為nr2b nmda受體拮抗劑之3,3-二氟哌啶胺基甲酸酯雜環化合物

Country Status (17)

Country Link
US (4) US10584127B2 (enExample)
EP (1) EP3303323B1 (enExample)
JP (1) JP6876625B2 (enExample)
KR (1) KR102613179B1 (enExample)
CN (1) CN107849010B (enExample)
AR (1) AR104837A1 (enExample)
AU (1) AU2016270677B2 (enExample)
BR (1) BR112017025023B1 (enExample)
CA (1) CA2987606C (enExample)
DK (1) DK3303323T3 (enExample)
ES (1) ES2784398T3 (enExample)
IL (1) IL255937B (enExample)
MX (1) MX380424B (enExample)
RU (1) RU2735277C2 (enExample)
TW (1) TWI721987B (enExample)
WO (1) WO2016196513A1 (enExample)
ZA (1) ZA201708006B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017002775A (es) 2014-09-15 2017-08-10 Rugen Holdings (Cayman) Ltd Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
US10221182B2 (en) 2015-02-04 2019-03-05 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
CA2987606C (en) 2015-06-01 2024-02-20 Rugen Holdings (Cayman) Limited 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists
CN106986874B (zh) * 2016-01-20 2019-09-24 西华大学 (1H-吡唑[3,4-d]嘧啶)-4-氨基衍生物及其作为IDO抑制剂在药物制备中的用途
WO2018098128A1 (en) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
IL297333B2 (en) 2020-04-17 2025-09-01 Honeybrains Llc Preparations and methods for treating neuropsychiatric disorders
CN117159541B (zh) * 2023-09-20 2026-05-26 南华大学 Nat10拮抗剂在制备预防和/或治疗癫痫的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068409A1 (en) 2001-02-23 2002-09-06 Merck & Co., Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
TW200510378A (en) * 2003-06-04 2005-03-16 Merck & Co Inc N-substituted nonaryl-heterocyclic nmda/nr2b antagonists

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3717867A1 (de) 1987-05-26 1988-12-15 Schiepe Stapelautomaten Gmbh Stapelvorrichtung
IL122649A (en) 1995-08-11 2001-08-26 Pfizer (1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same
GB9805977D0 (en) * 1998-03-19 1998-05-20 Silver Joshua D Improvements in variable focus optical devices
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
WO2005102390A2 (en) 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
US20070293515A1 (en) 2004-08-03 2007-12-20 Layton Mark E 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists
CA2591738A1 (en) * 2004-12-22 2006-06-29 Merck & Co., Inc. Process for making substituted piperidines
CA2603876A1 (en) 2005-04-19 2006-10-26 Merck & Co., Inc. N-alkyl-azacycloalkyl nmda/nr2b antagonists
WO2007061868A2 (en) 2005-11-17 2007-05-31 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
CA2662702A1 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Difluorinated piperidines for treatment of alzheimer's disease and related conditions
KR20090094338A (ko) 2006-12-27 2009-09-04 사노피-아벤티스 치환된 이소퀴놀린 및 이소퀴놀리논 유도체
US20110053951A1 (en) 2008-03-27 2011-03-03 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
US20100010565A1 (en) * 2008-07-09 2010-01-14 Samuel Victor Lichtenstein Extended range wireless muscular and neural stimulation
WO2010015637A1 (en) 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
EP2519241A2 (en) 2009-12-28 2012-11-07 Afraxis, Inc. Methods for treating autism
ES2734552T3 (es) * 2010-04-16 2019-12-10 Ac Immune Sa Compuestos novedosos para el tratamiento de enfermedades asociadas a proteínas amiloides o de tipo amiloide
US20130231348A1 (en) 2010-06-09 2013-09-05 Afraxis, Inc. 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS
WO2011159945A2 (en) 2010-06-16 2011-12-22 Afraxis, Inc. Methods for treating neurological conditions
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
JP6007417B2 (ja) 2011-05-31 2016-10-12 レセプトス エルエルシー 新規ｇｌｐ−１受容体安定剤および調節剤
AU2013251079B2 (en) * 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
EA029056B1 (ru) * 2012-12-11 2018-02-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение
CN105308049A (zh) 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
JP2017500287A (ja) * 2013-11-06 2017-01-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｇｓｋ−３阻害剤として有用な置換ピリジン誘導体
US9221796B2 (en) * 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists
BR112016025910A8 (pt) 2014-05-06 2021-07-13 Univ Northwestern uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos
US10030026B2 (en) 2014-06-04 2018-07-24 Rugen Holdings (Cayman) Limited Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists
MX2017002775A (es) 2014-09-15 2017-08-10 Rugen Holdings (Cayman) Ltd Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
US20180271869A1 (en) 2014-09-22 2018-09-27 Jie Liu Treatment of anxiety disorders and autism spectrum disorders
WO2016100349A2 (en) 2014-12-16 2016-06-23 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
US10221182B2 (en) 2015-02-04 2019-03-05 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
CA2987606C (en) 2015-06-01 2024-02-20 Rugen Holdings (Cayman) Limited 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists
WO2018098128A1 (en) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068409A1 (en) 2001-02-23 2002-09-06 Merck & Co., Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
TW200510378A (en) * 2003-06-04 2005-03-16 Merck & Co Inc N-substituted nonaryl-heterocyclic nmda/nr2b antagonists

Also Published As

Publication number Publication date
US10294230B2 (en) 2019-05-21
ES2784398T3 (es) 2020-09-24
JP6876625B2 (ja) 2021-05-26
EP3303323B1 (en) 2020-01-08
KR102613179B1 (ko) 2023-12-14
DK3303323T3 (da) 2020-03-23
CN107849010A (zh) 2018-03-27
NZ737780A (en) 2024-04-26
US20220024937A1 (en) 2022-01-27
CA2987606C (en) 2024-02-20
US10584127B2 (en) 2020-03-10
US20200299300A1 (en) 2020-09-24
MX2017015370A (es) 2018-03-15
IL255937B (en) 2021-06-30
RU2017142005A3 (enExample) 2019-11-19
AU2016270677A1 (en) 2017-12-14
BR112017025023B1 (pt) 2024-01-30
KR20180032533A (ko) 2018-03-30
US20180346476A1 (en) 2018-12-06
AU2016270677B2 (en) 2020-11-12
ZA201708006B (en) 2021-07-28
JP2018522831A (ja) 2018-08-16
EP3303323A1 (en) 2018-04-11
RU2017142005A (ru) 2019-07-09
RU2735277C2 (ru) 2020-10-29
EP3303323A4 (en) 2019-01-02
US11136328B2 (en) 2021-10-05
WO2016196513A1 (en) 2016-12-08
MX380424B (es) 2025-03-12
HK1253023A1 (en) 2019-06-06
TW201710248A (zh) 2017-03-16
IL255937A (en) 2018-01-31
AR104837A1 (es) 2017-08-16
CN107849010B (zh) 2021-11-09
BR112017025023A2 (pt) 2018-08-07
CA2987606A1 (en) 2016-12-08
US20180170935A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
US11136328B2 (en) 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
KR101749953B1 (ko) α7 양성 알로스테릭 조절제로서의 모르폴리노티아졸
CN106715435B (zh) 作为nr2b nmda受体拮抗剂的吡咯并嘧啶衍生物
KR20250021314A (ko) 비시클릭-치환된 글루타르이미드 세레블론 결합제
JP2017525677A (ja) 治療用化合物及びその使用方法
JP7120549B2 (ja) Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ
EP3642195A1 (en) Substituted 5-cyanoindole compounds and uses thereof
WO2016100349A2 (en) Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
CN106795163A (zh) 作为nr2b nmda受体拮抗剂的二氟乙基吡啶衍生物
AU2004237130A1 (en) Positive modulators of nicotinic acetylcholine receptors
TW201321384A (zh) 作為鈣通道阻斷劑之經取代之八氫吡咯并［１，２－ａ］吡□磺醯胺
EP3544610A1 (en) Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
JP2022553282A (ja) Ｔｒｅｋ（ｔｗｉｋ関連ｋ＋チャネル）チャネル機能のモジュレータ
HK1253023B (en) 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists
WO2003078441A1 (en) Aminomethyl-substituted thiazolobenzimidazole derivative